

BIOMARIN PHARMACEUTICAL INC  
 Form 4  
 October 31, 2014

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**BAFFI ROBERT**

2. Issuer Name and Ticker or Trading Symbol  
**BIOMARIN PHARMACEUTICAL INC [BMRN]**

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)

(Last) (First) (Middle)  
**C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE**

3. Date of Earliest Transaction (Month/Day/Year)  
**10/29/2014**

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 Officer (give title below) \_\_\_\_\_ Other (specify below)  
**EVP, Technical Operations**

(Street)  
**NOVATO, CA 94949**

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 \_\_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code	V	Amount	(A) or (D)	Price		
Common Stock					23,889	I		Shares Owned by Baffi Family Trust	
Common Stock	10/29/2014	10/29/2014	M		4,655	A	\$ 17.54	103,855	D
Common Stock	10/29/2014	10/29/2014	M		5,770	A	\$ 17.33	109,625	D

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common Stock	10/29/2014	10/29/2014	M	35,037	A	\$ 38.59	144,662	D
Common Stock	10/29/2014	10/29/2014	S V	45,462	D	\$ 81.0997 (1)	99,200	D
Common Stock	10/30/2014	10/30/2014	M	27,372	A	\$ 38.59	126,572	D
Common Stock	10/30/2014	10/30/2014	M	2,591	A	\$ 38.59	129,163	D
Common Stock	10/30/2014	10/30/2014	S V	29,963	D	\$ 81.6994 (2)	99,200	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Security (Instr. 3 and 4)	Amount or Number of Shares	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy) Common Stock	\$ 17.54	10/29/2014	10/29/2014	A	4,655	05/20/2007 <sup>(3)</sup>	11/20/2016	Common Stock	4,655
Stock Option (right to buy) Common Stock	\$ 17.33	10/29/2014	10/29/2014	A	5,770	12/07/2007 <sup>(4)</sup>	06/07/2017	Common Stock	5,770
Stock Option	\$ 38.59	10/29/2014	10/29/2014	A	35,037	11/22/2008 <sup>(5)</sup>	05/21/2018	Common Stock	35,037

(right to buy)  
Common Stock

Stock

Option

(right to buy)

\$ 38.59      10/30/2014      10/30/2014      A      27,372      11/22/2008      05/21/2018<sup>(5)</sup>

Common Stock 27,

Common Stock

Stock

Option

(right to buy)

\$ 38.59      10/30/2014      10/30/2014      A      2,591      11/22/2008<sup>(6)</sup>      05/21/2018

Common Stock 2,

Common Stock

## Reporting Owners

### Reporting Owner Name / Address

### Relationships

Director    10% Owner    Officer    Other

BAFFI ROBERT  
C/O BIOMARIN PHARMACEUTICAL INC.  
105 DIGITAL DRIVE  
NOVATO, CA 94949

EVP, Technical Operations

## Signatures

/s/ Laura Randall Woodhead,  
Attorney-in-Fact

10/31/2014

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The price in column 4 is a weighted average price. The price actually received ranged from \$81.00 to \$81.53. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price in column 4 is a weighted average price. The price actually received ranged from \$81.00 to \$81.96. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

(3) Option grant vests 6/48ths on May 20, 2007 and 1/48th on the 20th day of every month thereafter.

(4) Option grant vests 6/48ths on December 7, 2007 and 1/48th on the 7th day of every month thereafter.

(5) Option grant vests 6/48ths on November 22, 2008 and 1/48th on the 22nd day of every month thereafter.

(6) Option grant vests 6/48ths on November 22, 2008 and 1/48th on the 22nd day of every month thereafter.

(7) Reflects the number of stock options outstanding after the transaction from this specific stock option grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.